KORU Medical Systems, Inc. KRMD 深 沪
已收盘 11-13 16:00:00 美东时间
3.70
+0.010
+0.27%
华盛通- 最 高3.80
- 今 开3.66
- 成交量 21.91万股
- 最 低 3.51
- 昨 收 3.69
- 总市值 1.60亿
- 52周最高 6.608
- 市盈率 静 --
- 换手率 0.51%
- 52周最低 2.86
- 委 比 -20.00%
- 总股本 4337.52万
- 历史最高 12.84
- 量 比 0.71
- 振 幅 7.86%
- 历史最低 1.82
- 每 手 1
- 风险率 0.89%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | Stifel等多家大行上调CoreWeave目标价；杰富瑞首予康宁"买入"评级
今日重点评级关注：韦德布什：维持Cullinan Therapeutics"跑赢大市"评级，目标价从42美元升至44美元；HC Wainwright & Co.：维持WhiteFiber"买入"评级，目标价从34美元升至36美元
11-12 19:19
Piper Sandler Reiterates Neutral on KORU Medical Systems, Lowers Price Target to $4.5
Piper Sandler analyst Jason Bednar reiterates KORU Medical Systems (NASDAQ:KRMD) with a Neutral and lowers the price target from $5 to $4.5.
11-11 22:30
CORRECTION: KORU Medical Systems Q3 Adj. EPS $0.02 Beats $(0.02) Estimate, Sales $11.567M Beat $11.327M Estimate
KORU Medical Systems (NASDAQ:KRMD) reported quarterly earnings of $0.02 per share which beat the analyst consensus estimate of $(0.02) by 200 percent. The company reported quarterly sales of $11.567 million which beat the analyst consensus estimate of $11.327 million by 2.12 percent. This is a 11.20...
11-11 07:12
KORU Medical Systems Raises FY2026 Sales Guidance from $47.500M-$48.500M to $48.000M-$48.500M vs $48.030M Est
KORU Medical Systems (NASDAQ:KRMD) raises FY2026 sales outlook from $47.500 million-$48.500 million to $48.000 million-$48.500 million vs $48.030 million estimate.
11-11 05:14
KORU Medical Systems Narrows FY2026 Sales Guidance from $47.500M-$50.000M to $47.500M-$48.500M vs $48.688M Est
KORU Medical Systems (NASDAQ:KRMD) narrows FY2026 sales outlook from $47.500 million-$50.000 million to $47.500 million-$48.500 million vs $48.688 million estimate.
08-06 04:24
KORU Medical Systems Presents Data Titled 'Reducing Ergonomic Strain During Subcutaneous Monoclonal Antibody Administration' At Oncology Nursing Society Congress
KORU Medical Systems, Inc. (NASDAQ:KRMD) ("KORU Medical" or the "Company"), a leading medical technology company focused on innovative and patient-centric large volume subcutaneous infusion solutions, today announced
05-19 04:09
KORU Medical Systems shares are trading higher after the company reported better-than-expected Q1 sales results and reaffirmed its FY2026 sales guidance.
KORU Medical Systems shares are trading higher after the company reported bette...
05-07 05:15
Earnings Scheduled For May 6, 2026
Companies Reporting Before The Bell • Deluxe (NYSE:DLX) is expected to report q...
05-07 05:03
电话会总结 ｜ KORU Medical(KRMD)2025财年Q4业绩电话会核心要点
<span style="color:#999999;">编者按：聚焦公司高管观点与展望，深挖业绩背后的信息，助力投资者把握先机。</span><blockquote><p><span style="color:#fa1432;"><strong>业绩回顾</strong></span></p></blockquote><p>• 根据KORU Medical业绩会实录，以下是财务业绩回顾摘要： ## 1. 财务业绩 **营收表现：** - 第四季度营收1,090万美元，同比增长23%，连续第三个季度实现超过20%的营收增长 - 全年营收4,110万美元，同比增长22%（2024年为3,360万美元） **分业务营收：** - 国内核心业务：第四季度同比增长18%，全年增长11% - 国际核心业务：第四季度同比增长71%，全年增长80%（剔除分销商调整影响后，潜在增长率为73%） - PST业务：第四季度同比下降30% **利润率表现：** - 毛利率：全年62.3%，较上年同
03-18 12:25
美股大行评级 | 韦德布什升美光科技目标价升至500美元，维持"跑赢大市"评级
今日重点评级关注：Piper Sandler：维持Allogene疗法"超配"评级，目标价从7美元升至8美元；B. Riley证券：维持Oncology Institute"买入"评级，目标价从6美元升至8美元
03-16 18:19
